Baird raised the firm’s price target on Alcon to $95 from $90 and keeps an Outperform rating on the shares. The firm said with cataract and contact lens demand trends holding in well, pricing tailwinds persisting, and Fx/inflationary headwinds likely abating later this year/into 2024, they continue to see a fairly clear path to MSD+ organic revenue growth/healthy margin expansion for Alcon over coming years.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALC: